<DOC>
	<DOCNO>NCT00902603</DOCNO>
	<brief_summary>The Ventavis® ( iloprost ) Registry multicenter , observational , U.S.-based study longitudinally follow patient pulmonary arterial hypertension ( PAH ) receive therapy Ventavis® least 3 month . Patients diagnose WHO Group I PAH stable regimen commercial Ventavis® follow maximum 2 year time enrollment . Data collect via patient interview review medical record . Quarterly data collection include capture medication Ventavis® adherence data .</brief_summary>
	<brief_title>Ventavis® Registry Protocol</brief_title>
	<detailed_description>The Ventavis® ( iloprost ) Registry multicenter , observational , U.S.-based study longitudinally follow patient pulmonary arterial hypertension ( PAH ) receive therapy Ventavis® least 3 month . Patients diagnose WHO Group I PAH stable regimen commercial Ventavis® follow maximum 2 year time enrollment . All data collect via patient interview and/or review medical record , well I-neb® downloads use INSIGHT software . Adherence Ventavis® compare targeted instruction inhalation technique respiratory therapist designee , well participation PAH patient support group ( applicable ) . Quarterly data collection include capture PAH non-PAH medication Ventavis® adherence data ; Ventavis® adherence data also collect one month study entry .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>1 . Have current diagnosis WHO Group I PAH 2 . Have initiate therapy commercial Ventavis® administer via portable nebulizer least 3 month prior study enrollment , either commercial product participation Actelion 's Clinical Study AC063A302 3 . Age &gt; = 18 year old time enrollment 1 . Meet criteria inclusion WHO Groups II , III , IV V PAH 2 . Are currently commercial Ventavis® 3 . Have initiate therapy commercial Ventavis® administer via portable nebulizer le 3 month prior study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>Ventavis®</keyword>
	<keyword>iloprost</keyword>
</DOC>